Last 46 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.08 | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 3.16 | 16.38 | 32.99 | 10.91 | 7.23 | 8.17 | 32.26 | 151.52 | 156.27 | 791.54 | — | — | — |
| — | +100.4% | +2.3% | -92.8% | -95.4% | -99.0% | — | — | — | — | — | — | — | |
| P/B Ratio | 0.23 | 0.93 | 1.57 | 0.59 | 0.53 | 1.24 | 6.77 | 13.91 | 22.38 | 104.52 | 207.35 | 229.32 | 115.48 |
| — | -25.0% | -76.8% | -95.8% | -97.6% | -98.8% | -96.7% | -93.9% | -80.6% | +4.7% | +52.2% | -96.0% | -98.4% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Tonix Pharmaceuticals Holding Corp.'s operating margin was -1005.1% in Q3 2025, up 411.1 pp QoQ and down 453.9 pp YoY. The trailing four-quarter average of -988.2% exceeds the current quarter, suggesting the latest result may reflect seasonal weakness or a one-off headwind. Gross margin expanded 30.2% YoY, indicating pricing power or improving input costs.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 23.1% | 58.4% | -63.8% | 61.2% | 54.2% | 44.9% | -52.5% | 33.1% | -2.1% | 40.5% | — | — | — |
| — | +30.2% | -21.5% | +84.7% | +2691.9% | +10.9% | — | — | — | — | — | — | — | |
| Operating Margin | -1354.3% | -1005.1% | -1416.2% | -660.9% | -870.6% | -551.2% | -831.5% | -860.2% | -723.2% | -705.6% | — | — | — |
| — | -82.4% | -70.3% | +23.2% | -20.4% | +21.9% | — | — | — | — | — | — | — | |
| Net Margin | -1288.3% | -972.9% | -1415.0% | -692.8% | -856.2% | -503.6% | -3567.8% | -601.9% | -723.0% | -701.3% | — | — | — |
| — | -93.2% | +60.3% | -15.1% | -18.4% | +28.2% | — | — | — | — | — | — | — |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -106.1% | -16.0% | -16.2% | -10.5% | -20.7% | -24.4% | -104.9% | -14.0% | -24.1% | -21.4% | -18.5% | -17.7% | -14.5% |
| — | +34.4% | +84.5% | +24.8% | +14.3% | -14.1% | -465.6% | +21.1% | -66.2% | -80.5% | -87.4% | -43.1% | -3.5% | |
| ROA | -82.0% | -14.6% | -14.9% | -9.5% | -17.1% | -17.2% | -76.6% | -10.3% | -18.6% | -18.7% | -16.7% | -16.3% | -13.5% |
| — | +15.4% | +80.6% | +8.2% | +7.8% | +8.1% | -357.7% | +36.8% | -37.5% | -67.5% | -80.8% | -43.4% | -4.3% | |
| ROIC | -150.3% | -58.6% | -45.9% | -25.3% | -33.5% | -22.8% | -17.4% | -15.9% | -20.0% | -18.3% | -20.7% | -27.9% | -27.7% |
| — | -156.5% | -164.2% | -58.8% | -67.7% | -25.1% | +15.8% | +43.0% | +27.8% | +15.6% | -8.4% | +23.0% | +61.6% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has improved 197.2% YoY to 9.89x, strengthening the short-term liquidity position.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.04 | 0.00 | 0.00 | 0.00 | 0.04 | 0.12 | 0.23 | 0.09 | 0.09 | 0.01 | 0.01 | 0.01 | 0.00 |
| — | -98.4% | -98.7% | -96.6% | -59.2% | +1130.7% | +2410.7% | +1363.8% | +2435.2% | +145.9% | +137.9% | +60.8% | -16.1% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 6.50 | 9.89 | 7.53 | 12.31 | 6.50 | 3.33 | 1.15 | 1.47 | 2.53 | 1.77 | 2.78 | 6.40 | 7.19 |
| — | +197.2% | +556.4% | +737.9% | +157.0% | +88.4% | -58.8% | -77.1% | -64.8% | -84.4% | -76.9% | -35.7% | -17.4% | |
| Quick Ratio | 6.04 | 9.62 | 7.22 | 11.64 | 6.04 | 2.81 | 0.72 | 0.87 | 1.78 | 1.02 | 2.04 | 6.40 | 7.19 |
| — | +242.8% | +904.9% | +1243.7% | +239.3% | +176.2% | -64.8% | -86.5% | -75.2% | -91.0% | -83.1% | -35.7% | -17.4% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 46 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorDCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare business quality, growth, and profitability against top sector peers.
Start ComparisonQuick answers to the most common questions about buying TNXP stock.
Tonix Pharmaceuticals Holding Corp.'s current P/E is -0.1x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Tonix Pharmaceuticals Holding Corp.'s current operating margin is -1354.3%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Tonix Pharmaceuticals Holding Corp.'s business trajectory between earnings reports.